At LSI USA ‘24, a panel of industry leaders delved into the transformative potential of brain-computer interface (BCI) technologies. This rapidly evolving field promises to address the limitations of the human body, particularly for individuals with motor impairments, by enabling direct communication between the brain and external devices. The panel, featuring Tom Oxley, CEO of Synchron, and Andy Rasdal, former CEO of Dexcom, provided invaluable insights into the intricacies of BCI technology, its commercial prospects, and the strategic considerations that medtech innovators must navigate.
What Are BCI Technologies?
Brain-computer interfaces are groundbreaking technologies that detect and interpret brain signals to control external devices. BCIs enable individuals to use their thoughts to interact with computers, prosthetics, and other assistive technologies.
Tom Oxley described BCIs as “primarily a sensing technology,” noting that these devices detect brain activity, predict intended actions, and translate those predictions into commands for external devices. He added, “BCI technologies promise to take signals from the brain, create a new Bluetooth input into a digital device, and restore control of that device.”
The Road to Commercialization
Bringing a new technology like BCIs from concept to market is a multifaceted and challenging process. Andy Rasdal emphasized the importance of having a skilled and aligned team. “It’s about building a great team with a unified vision and staying laser-focused on that goal,” Rasdal explained. He pointed to his experience at Dexcom, where building a dependable, reliable product was key to the company’s success.
Rasdal also highlighted the need for a well-developed technology that not only works but works consistently in real-world settings. “Delivering a functional, reliable product is paramount,” he noted.
Navigating Funding and Investor Engagement
For medtech startups, securing funding is one of the biggest hurdles for medtech startups. Oxley shared Synchron’s experience in attracting investment: “We haven’t just gone for traditional MedTech investors. We’ve looked for different ways to secure funding. It’s crucial to tell your story to a variety of investor groups,” Oxley said. This approach led to significant investments, including a $75 million Series C round backed by Arch Ventures and high-profile investors such as Bill Gates and Jeff Bezos.
For medtech companies exploring novel technologies like BCIs, building a diverse investor base can help expand funding opportunities.
Scaling Manufacturing for BCI Technologies
Once a technology is ready for commercialization, scaling production is the next major challenge. Synchron has taken innovative steps to address this need by investing in specialized manufacturing processes. Oxley explained, “We had to develop a completely novel manufacturing process using sputtering technology. We worked with a partner to build that manufacturing line to ensure we could meet demand and maintain quality as we scale.”
This focus on scalable manufacturing is essential for medtech companies looking to bring innovative technologies like BCIs to market.
The Future of BCIs
The potential applications of BCI technology extend far beyond motor impairments. Oxley sees a future where BCIs could address a wide range of neurological conditions. “The FDA is beginning to view BCIs as synonymous with neuroprosthetics, where these devices can restore brain functions like hearing, sight, memory, and even cognitive abilities,” Oxley said. This broader perspective on BCI applications suggests that the market for this technology will grow significantly in the coming years.
The full recording of the panel can be found in LSI’s resource hub at the link below:
BCI technologies are poised to revolutionize healthcare by expanding the boundaries of what is possible in human-machine interaction. As the panel at LSI USA ‘24 Medtech Converence emphasized, the commercialization of BCIs requires careful planning, robust technology, and an effective approach to regulatory and manufacturing challenges. For investors, the BCI sector represents a dynamic opportunity to support medtech innovations that can transform the lives of millions, especially those facing physical and neurological challenges. The future of neurotechnology is bright, and the potential to impact healthcare is immense.